Literature DB >> 18406014

Conformationally constrained analogues of N'-(4-tert-butylbenzyl)-N-(4-methylsulfonylaminobenzyl)thiourea as TRPV1 antagonists.

Ju-Ok Lim1, Mi-Kyoung Jin, HyungChul Ryu, Dong Wook Kang, Jeewoo Lee, Larry V Pearce, Richard Tran, Attila Toth, Peter M Blumberg.   

Abstract

A series of bicyclic analogues having indan and tetrahydronaphthalene templates in the A-region were designed as conformationally constrained analogues of our previously reported potent TRPV1 antagonists (1, 3). The activities for rat TRPV1 of the conformationally restricted analogues were moderately or markedly diminished, particularly in the case of the tetrahydronaphthalene analogues. The analysis indicated that steric constraints at the benzylic position in the bicyclic analogues may be an important factor for their unfavorable interaction with the receptor.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18406014      PMCID: PMC3420357          DOI: 10.1016/j.ejmech.2008.02.026

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  16 in total

Review 1.  Vanilloid (Capsaicin) receptors and mechanisms.

Authors:  A Szallasi; P M Blumberg
Journal:  Pharmacol Rev       Date:  1999-06       Impact factor: 25.468

2.  The capsaicin receptor: a heat-activated ion channel in the pain pathway.

Authors:  M J Caterina; M A Schumacher; M Tominaga; T A Rosen; J D Levine; D Julius
Journal:  Nature       Date:  1997-10-23       Impact factor: 49.962

3.  The cloned capsaicin receptor integrates multiple pain-producing stimuli.

Authors:  M Tominaga; M J Caterina; A B Malmberg; T A Rosen; H Gilbert; K Skinner; B E Raumann; A I Basbaum; D Julius
Journal:  Neuron       Date:  1998-09       Impact factor: 17.173

4.  Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide.

Authors:  P M Zygmunt; J Petersson; D A Andersson; H Chuang; M Sørgård; V Di Marzo; D Julius; E D Högestätt
Journal:  Nature       Date:  1999-07-29       Impact factor: 49.962

Review 5.  Euphorbium: modern research on its active principle, resiniferatoxin, revives an ancient medicine.

Authors:  G Appendino; A Szallasi
Journal:  Life Sci       Date:  1997       Impact factor: 5.037

6.  High affinity antagonists of the vanilloid receptor.

Authors:  Yun Wang; Tamas Szabo; Jacqueline D Welter; Attila Toth; Richard Tran; Jiyoun Lee; Sang Uk Kang; Young-Ger Suh; Peter M Blumberg; Jeewoo Lee
Journal:  Mol Pharmacol       Date:  2002-10       Impact factor: 4.436

7.  High-affinity partial agonists of the vanilloid receptor.

Authors:  Yun Wang; Attila Toth; Richard Tran; Tamas Szabo; Jacqueline D Welter; Peter M Blumberg; Jiyoun Lee; Sang-Uk Kang; Ju-Ok Lim; Jeewoo Lee
Journal:  Mol Pharmacol       Date:  2003-08       Impact factor: 4.436

Review 8.  The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept.

Authors:  Arpad Szallasi; Daniel N Cortright; Charles A Blum; Samer R Eid
Journal:  Nat Rev Drug Discov       Date:  2007-05       Impact factor: 84.694

9.  N-(3-acyloxy-2-benzylpropyl)-N'-[4-(methylsulfonylamino)benzyl]thiourea analogues: novel potent and high affinity antagonists and partial antagonists of the vanilloid receptor.

Authors:  Jeewoo Lee; Jiyoun Lee; Myungshim Kang; Myoungyoup Shin; Ji-Min Kim; Sang-Uk Kang; Ju-Ok Lim; Hyun-Kyung Choi; Young-Ger Suh; Hyeung-Geun Park; Uhtaek Oh; Hee-Doo Kim; Young-Ho Park; Hee-Jin Ha; Young-Ho Kim; Attila Toth; Yun Wang; Richard Tran; Larry V Pearce; Daniel J Lundberg; Peter M Blumberg
Journal:  J Med Chem       Date:  2003-07-03       Impact factor: 7.446

10.  Alpha-substituted N-(4-tert-butylbenzyl)-N'-[4-(methylsulfonylamino)benzyl]thiourea analogues as potent and stereospecific TRPV1 antagonists.

Authors:  Jae-Uk Chung; Su Yeon Kim; Ju-Ok Lim; Hyun-Kyung Choi; Sang-Uk Kang; Hae-Seok Yoon; Hyungchul Ryu; Dong Wook Kang; Jeewoo Lee; Bomi Kang; Sun Choi; Attila Toth; Larry V Pearce; Vladimir A Pavlyukovets; Daniel J Lundberg; Peter M Blumberg
Journal:  Bioorg Med Chem       Date:  2007-06-26       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.